Tender detail
Omalizumab rebate agreements 2025–2029
Summary
The tender concerns the supply or supply rights for medicines containing omalizumab under open-house biologics rebate agreements. The contract is based on uniform terms, with no individual negotiations and no exclusivity granted. The contract term is up to 24 months starting on 01/11/2025 and ends no later than 31/10/2027. The exact participation and contract conditions must be checked in the tender documents.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.